➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Moodys
Medtronic
McKesson
Mallinckrodt

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 8,007,796

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,007,796
Title:Means and methods for the treatment of tumorous diseases
Abstract: The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.
Inventor(s): Baeuerle; Patrick (Gauting, DE), Kufer; Peter (Moosburg, DE), Klinger; Matthias (Gilching, DE), Leo; Eugen (Koln, DE)
Assignee: Micromet AG (Munich, DE)
Application Number:12/095,951
Patent Claims:see list of patent claims

Details for Patent 8,007,796

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen BLINCYTO blinatumomab INJECTABLE;INJECTION 125557 001 2014-12-03   Start Trial Micromet AG (Munich, DE) 2025-12-16 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Express Scripts
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.